(NASDAQ:HOWL), – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to […]
(TSX:SJ), MONTREAL, Nov. 04, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX:SJ). Open to: Investors, analysts and all interested parties Date: Wednesday November 5, 2025 Time: 10:00 AM Eastern Standard Time (EST) Live Webcast: https://meetings.lumiconnect.com/400-700-172-835 Call: (+1) 800 990 2777 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH
(NASDAQ:MDGL), Third-quarter 2025 Rezdiffra(TM) (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash,
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors GlobeNewswire November 04, 2025 Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million
(NasdaqGM:BGL),(NasdaqGM:BGLWW), NEW YORK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) — Blue Gold Limited (Nasdaq: BGL) (“Blue Gold” or the “Company”), a next-generation gold development and technology company, today announced the appointment of Nathan Dionne as Chief Technology Officer (CTO), effective immediately. As CTO, Mr. Dionne will lead the delivery of the Company's digital strategy, overseeing
(NASDAQ:AMPG),(NASDAQ:AMPGW), HAUPPAUGE, N.Y., Nov. 04, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private ORAN 5G, and other communications networks, including the design of complete 5G/6G systems and a global distributor of packages and lids for integrated circuits assembly,
Relmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder Cancer GlobeNewswire November 04, 2025 Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized controlled
(TSX-V:ABI),(OTC US:ABMBF),(Other OTC:ABMBF), ROUYN-NORANDA, Quebec, Nov. 04, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (TSXV: ABI) (OTCQB: ABMBF) (“Abcourt” or the “Corporation“) wishes to update its shareholders regarding the Corporation's upcoming annual meeting, which is to be held at Lavery de Billy's offices at 1 Place Ville-Marie, 40th Floor, Montreal, Quebec, H3B 4M4 on Wednesday,
Geography Shouldn't Determine Access to Justice: New Report Reveals Deep Inequities in Forensic Evidence Collection for Sexual Assault Survivors in Canada's Remote and Indigenous Communities GlobeNewswire November 04, 2025 TORONTO, Nov. 04, 2025 (GLOBE NEWSWIRE) — A groundbreaking new report from She Matters, funded by the Ministry of Women and Gender Equality Canada (WAGE), reveals
(TASE:KMDA.TA),(NASDAQ:KMDA), REHOVOT, Israel, and HOBOKEN, N.J. , Nov. 04, 2025 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the first patient was enrolled into an investigator-initiated post-marketing